Vivek Pradhan

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

Séverine Vermeire, William J. Sandborn, Silvio Danese et al. · The Lancet · 2017 · 197 citations

Life Sciences, Immunology, Pharmacotherapy +14

Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study

Megan N. Landis, Mark Arya, Stacy Smith et al. · British Journal of Dermatology · 2022 · 63 citations · Full text

Medicine, Dermatology, Pharmacology +16

Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study

Christopher Tehlirian, Ravi Shankar Prasad Singh, Vivek Pradhan et al. · Journal of the American Academy of Dermatology · 2022 · 55 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Choice of test for association in small sample unordered <i>r</i> × <i>c</i> tables

Stian Lydersen, Vivek Pradhan, Pralay Senchaudhuri et al. · Statistics in Medicine · 2007 · 47 citations · Full text

Public Health, Biostatistics, Categorical Data Analysis +13

A comparative study of the bias corrected estimates in logistic regression

Tapabrata Maiti, Vivek Pradhan · Statistical Methods in Medical Research · 2008 · 44 citations

Public Health, Biostatistics, Experimental Design +16